Abstract:BACKGROUND:Neuroinflammation is characterized by microglial activation and the increased levels of cytokines and chemokines in the central nervous system (CNS). Recent evidence has implicated both beneficial and toxic roles of microglia when over-activated upon nerve injury or in neurodegenerative diseases, including Alzheimer's disease (AD). The low-density lipoprotein receptor-related protein 1 (LRP1) is a major receptor for apolipoprotein E (apoE) and amyloid-β (Aβ), which play critical roles in AD pathogenesis. LRP1 regulates inflammatory responses in peripheral tissues by modulating the release of inflammatory cytokines and phagocytosis. However, the roles of LRP1 in brain innate immunity and neuroinflammation remain unclear.METHODS:In this study, we determined whether LRP1 modulates microglial activation by knocking down Lrp1 in mouse primary microglia. LRP1-related functions in microglia were also assessed in the presence of LRP1 antagonist, the receptor-associated protein (RAP). The effects on the production of inflammatory cytokines were measured by quantitative real-time PCR (qRT-PCR) and enzyme-linked immunosorbent assay (ELISA). Potential involvement of specific signaling pathways in LRP1-regulated functions including mitogen-activated protein kinases (MAPKs) and nuclear factor-κB (NF-κB) were assessed using specific inhibitors.RESULTS:We found that knocking down of Lrp1 in mouse primary microglia led to the activation of both c-Jun N-terminal kinase (JNK) and NF-κB pathways with corresponding enhanced sensitivity to lipopolysaccharide (LPS) in the production of pro-inflammatory cytokines. Similar effects were observed when microglia were treated with LRP1 antagonist RAP. In addition, treatment with pro-inflammatory stimuli suppressed Lrp1 expression in microglia. Interestingly, NF-κB inhibitor not only suppressed the production of cytokines induced by the knockdown of Lrp1 but also restored the down-regulated expression of Lrp1 by LPS.CONCLUSIONS:Our study uncovers that LRP1 suppresses microglial activation by modulating JNK and NF-κB signaling pathways. Given that dysregulation of LRP1 has been associated with AD pathogenesis, our work reveals a critical regulatory mechanism of microglial activation by LRP1 that could be associated with other AD-related pathways thus further nominating LRP1 as a potential disease-modifying target for the treatment of AD.

The functional role of the second NPXY motif of the LRP1 beta-chain in tissue-type plasminogen activator-mediated activation of N-methyl-D-aspartate receptors

A multimolecular signaling complex including PrPC and LRP1 is strictly dependent on lipid rafts and is essential for the function of tissue plasminogen activator

Tissue-type Plasminogen Activator and the Low-Density Lipoprotein Receptor–related Protein Induce Akt Phosphorylation in the Ischemic Brain

Ligand binding to LRP1 transactivates Trk receptors by a Src family kinase-dependent pathway

Roles of the AMPA Receptor Subunit GluA1 but Not GluA2 in Synaptic Potentiation and Activation of ERK in the Anterior Cingulate Cortex

Requirement of Extracellular Signal-Regulated Kinase/Mitogen-Activated Protein Kinase for Long-Term Potentiation in Adult Mouse Anterior Cingulate Cortex

Tissue-type Plasminogen Activator (tpa) Modulates the Postsynaptic Response of Cerebral Cortical Neurons to the Presynaptic Release of Glutamate

Low-density lipoprotein receptor related protein-1 (LRP1)-dependent cell signaling promotes neurotrophic activity in embryonic sensory neurons

LAR receptor phospho-tyrosine phosphatases regulate NMDA-receptor responses

The NMDA receptor regulates integrin activation, ATP release and arterial thrombosis through store-operated Ca2+ entry in platelets

LRP1 Triggers Pro-inflammatory Cell-signaling in Response to Extracellular Tau Independently of the NMDA Receptor

Modulations of the neuronal trafficking of tissue-type plasminogen activator (tPA) influences glutamate release

Low-density Lipoprotein Receptor-Related Protein 1 (LRP1) Regulates the Stability and Function of GluA1 Α-Amino-3-hydroxy-5-methyl-4-isoxazole Propionic Acid (AMPA) Receptor in Neurons.

The LRP1/CD91 ligands, tissue-type plasminogen activator, α2-macroglobulin, and soluble cellular prion protein have distinct co-receptor requirements for activation of cell-signaling

Blood tissue Plasminogen Activator (tPA) of liver origin contributes to neurovascular coupling involving brain endothelial N-Methyl-D-Aspartate (NMDA) receptors

Enhanced poly(ADP-ribose) polymerase-1 activation contributes to recombinant tissue plasminogen activator-induced aggravation of ischemic brain injury in vivo

Protein Kinase C-Mediated Phosphorylation and 2-1 Interdependently Regulate NMDA Receptor Trafficking and Activity

LAR receptor protein tyrosine phosphatases in the development and maintenance of excitatory synapses

Tissue-type Plasminogen Activator Protects Neurons from Excitotoxin-Induced Cell Death Via Activation of the ERK 1/2–CREB–ATF3 Signaling Pathway

Low-density lipoprotein receptor-related protein-1 (LRP1) in the glial lineage modulates neuronal excitability

LRP1 Modulates the Microglial Immune Response Via Regulation of JNK and NF-κB Signaling Pathways